Approved HIV Drugs
Approved HIV Drugs
FDA Review Finds No Link Between Abacavir Use and Heart Attacks
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
A meta-analysis by the U.S. Food and Drug Administration (FDA) offers further evidence that the NRTI abacavir (Ziagen, also in the Epzicom and Trizivir coformulations) is not significantly associated with an increased risk of myocardial infarction, according to a report published in the August 28, 2012, online edition of the Journal of Acquired Immune Deficiency Syndromes.
ICAAC 2012: Stribild Quad Pill Has Potent Anti-HIV Activity with Fewer Side Effects
- Details
- Category: HIV Treatment
- Published on Tuesday, 11 September 2012 00:00
- Written by Liz Highleyman
An integrated analysis of data from Phase 2 and 3 trials, presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco, showed that the newly approved Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) single-tablet regimen had antiviral efficacy at least as good as comparison regimens, and was associated with fewer adverse events than Atripla or boosted atazanavir (Reyataz).
AIDS 2012: Switching from Protease Inhibitor to Complera Maintains Viral Suppression, Lowers Lipids
- Details
- Category: Approved HIV Drugs
- Published on Friday, 03 August 2012 00:00
- Written by Liz Highleyman
People who switched to the all-in-one Complera (rilpivirine/tenofovir/emtricitabine) combination pill from a boosted protease inhibitor continued to have undetectable viral load and on average had improved lipid profiles associated with lower cardiovascular risk, according to study findings presented at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC. 
AIDS 2012: Raltegravir Remains Effective and Well-tolerated at 5 Years
- Details
- Category: HIV Treatment
- Published on Tuesday, 07 August 2012 00:00
- Written by Liz Highleyman
The HIV integrase inhibitor raltegravir (Isentress) continued to demonstrate good efficacy as part of a first-line antiretroviral regimen and had a consistently favorable safety profile at 240 weeks in the STARTMRK trial, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.Another long-term analysis showed continued efficacy for treatment-experienced patients with extensive drug resistance.
AIDS 2012: Once-daily Maraviroc + Boosted Atazanavir Looks Promising at 96 Weeks
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 25 July 2012 00:00
- Written by Liz Highleyman
A NRTI-sparing regimen of maraviroc (Selzentry) plus ritonavir-boosted atazanavir (Reyataz) produced good virological suppression and was generally well tolerated through 96 weeks, according to a study presented Tuesday at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.
More Articles...
- AIDS 2012: Changing Epidemiology of Opportunistic Infections in the ART Era
- NRTI-sparing Atazanavir + Raltegravir: Conflicting Data for Naive and Experienced HIV Patients
- Raltegravir Shows Long-term Treatment Benefit, Appears Useful for Post-Exposure Prevention
- FDA Approves New Fosamprenavir Dose Regimen, Nevirapine Tablets for HIV+ Children
Web Design and Development by